Haven't had much time lately? Here's what you may have missed in the last few months
09 Dec 2016
Hepatocellular carcinoma patients who have failed sorafenib therapy can derive an overall survival benefit from regorafenib
07 Dec 2016
Improved progression-free survival with obinutuzumab- versus rituximab-based therapy in patients newly diagnosed with follicular lymphoma
06 Dec 2016
Canadian researchers identify a role for the cardiac drugs perindopril and bisoprolol in the prevention of trastuzumab-mediated cardiotoxicity
05 Dec 2016
Single-agent vascular endothelial growth factor inhibitor therapy remains the optimal choice in the first-line setting of metastatic clear cell renal...
02 Dec 2016
Preliminary results suggest that a biosimilar formulation plus a taxane may achieve comparable overall response rates to trastuzumab plus a taxane in...
P. Schmid says that for many years oncologists used single agent endocrine therapy and now there are substantial results for combination treatment with CDK4/6 inhibitors in first-line metastatic breast cancer (mBC). However, the role for single agent endocrine therapy remains in cases of low disease activity, slow progressing disease, long disease-free interval. Long term outcome data with early use of CDK4/6 inhibitors are expected and it should be elucidated what happens to patients upon progression to CDK4/6 inhibition.